Your browser doesn't support javascript.
loading
Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy.
Statland, Jeffrey M; Campbell, Craig; Desai, Urvi; Karam, Chafic; Díaz-Manera, Jordi; Guptill, Jeffrey T; Korngut, Lawrence; Genge, Angela; Tawil, Rabi N; Elman, Lauren; Joyce, Nanette C; Wagner, Kathryn R; Manousakis, Georgios; Amato, Anthony A; Butterfield, Russell J; Shieh, Perry B; Wicklund, Matthew; Gamez, Josep; Bodkin, Cynthia; Pestronk, Alan; Weihl, Conrad C; Vilchez-Padilla, Juan J; Johnson, Nicholas E; Mathews, Katherine D; Miller, Barry; Leneus, Ashley; Fowler, Marcie; van de Rijn, Marc; Attie, Kenneth M.
  • Statland JM; Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA.
  • Campbell C; Department of Pediatrics and Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada.
  • Desai U; Carolinas MDA Care Center, Atrium Health, Charlotte, North Carolina, USA.
  • Karam C; Neuromuscular Division, Oregon Health & Science University, Portland, Oregon, USA.
  • Díaz-Manera J; Neuromuscular Diseases Unit, Neurology Department, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.
  • Guptill JT; Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain.
  • Korngut L; John Walton Muscular Dystrophy Research Centre, Newcastle University Translational and Clinical Research Institute, Newcastle, UK.
  • Genge A; Department of Neurology, Duke University School of Medicine, Durham, North Carolina, USA.
  • Tawil RN; University of Calgary, Calgary, Alberta, Canada.
  • Elman L; Montreal Neurological Institute, Montreal, Quebec, Canada.
  • Joyce NC; University of Rochester School of Medicine, Rochester, New York, USA.
  • Wagner KR; University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Manousakis G; University of California Davis Medical Center, Davis, California, USA.
  • Amato AA; Johns Hopkins School of Medicine, Kennedy Krieger Institute, Baltimore, Maryland, USA.
  • Butterfield RJ; Department of Neurology, University of Minnesota, Minneapolis, Minnesota, USA.
  • Shieh PB; Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Wicklund M; Departments of Neurology and Pediatrics, University of Utah, Salt Lake City, Utah, USA.
  • Gamez J; University of California Los Angeles, Los Angeles, California, USA.
  • Bodkin C; University of Colorado, Aurora, Colorado, USA.
  • Pestronk A; Department of Medicine, GMA Clinic, European Reference Network on Rare Neuromuscular Diseases (ERN EURO-NMD) and Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Weihl CC; Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Vilchez-Padilla JJ; Washington University School of Medicine, St. Louis, Missouri, USA.
  • Johnson NE; Washington University School of Medicine, St. Louis, Missouri, USA.
  • Mathews KD; Hospital UIP La Fe, Neuromuscular Reference Centre, Valencia, Spain.
  • Miller B; Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain.
  • Leneus A; Virginia Commonwealth University, Richmond, Virginia, USA.
  • Fowler M; Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.
  • van de Rijn M; Acceleron Pharma, Cambridge, Massachusetts, USA.
  • Attie KM; Acceleron Pharma, Cambridge, Massachusetts, USA.
Muscle Nerve ; 66(1): 50-62, 2022 07.
Article en En | MEDLINE | ID: mdl-35428982

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por Citomegalovirus / Distrofia Muscular Facioescapulohumeral Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por Citomegalovirus / Distrofia Muscular Facioescapulohumeral Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Humans Idioma: En Año: 2022 Tipo del documento: Article